International,Multi-Center,Open Label,Randomized Study Assessing the Safety and Efficacy of a Monthly Dosing Regimen of Ozarelix Versus Goserelin Depot in Men With Prostate Cancer

Prostate Cancer Clinical Trial

Official title:

Phase 2 Study Assessing the Safety and Efficacy of a Monthly Dosing Regimen of Ozarelix Versus Goserelin Depot (Zoladex®) in Men With Prostate Cancer

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT01252693
• Other study ID #: SPI-153-10-1
• Status: Completed
• Phase: Phase 2
• Start date: November 2010
• Est. completion date: May 2015

Study information

• Verified date: September 2021
• Source: Spectrum Pharmaceuticals, Inc
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

The aim of this study is to assess the safety and efficacy of a monthly regimen of ozarelix administered subcutaneously (SC) versus Goserelin depot administered subcutaneously in men with Prostate Cancer. This is an international, multi-center, randomized, open label 84 days study. Men who are at least 18 years of age or older, with histologically proven prostate cancer of all stages, in whom endocrine treatment is indicated will be eligible for study entry.

Description:

Prospective study subjects will undergo screening procedures. Approximately 214 eligible patients will enter the study. Patients will be randomized in a 1:1 ratio to one of two treatment arms (Ozarelix or Goserelin). Eligible patients randomized to the ozarelix group will receive two SC injections of ozarelix 65 mg in the abdomen on Day 1 (left lower quadrant, LLQ and right lower quadrant, RLQ), followed by a SC injection of 65 mg of Ozarelix (abdomen LLQ) on day 8 and will receive 2 additional SC injections of Ozarelix on days 28 and 56 (alternating injection sites). Eligible patients randomized to Goserelin will receive one 3.6 mg SC injection in the abdomen (LLQ or RLQ), followed by a 3.6 mg SC injection on Days 28 and 56 (alternating injection sites). Ozarelix will be reconstituted and administered as a 65 mg injection. Patients will receive two Ozarelix 65 mg subcutaneous injections (SC) on Day 1, and one 65 mg SC injection on day 8, followed by one 65 mg injection on days 28 and 56. The patients will receive one Goserelin 3.6 mg SC injection at baseline, Day 28 and Day 56.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 203
• Est. completion date: May 2015
• Est. primary completion date: September 2014
• Accepts healthy volunteers: No
• Gender: Male
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• Patients, aged 18 years or older, with histologically proven prostate cancer of any stages, for whom endocrine treatment is indicated.

• Screening testosterone > 1.5 ng/ml

• Life expectancy of at least 12 months

• ECOG score of = 2

• Patient has reviewed and signed Informed consent form

• Patient understands and is willing to comply with the protocol

Exclusion Criteria:

• Any hormone therapy prior to study entrance

• Any patient at risk of urinary tract obstruction or spinal cord compression due to potential testosterone surge

• History of severe uncontrolled asthma, anaphylactic reactions, or severe urticaria and/or angioedema

• History of hypersensitivity towards any components of the study drug

• History or presence of any other malignancy other than treated squamous cell /basal cell carcinoma of the skin within the last five years

• ECG at screening showing QTc >450 ms, or family history of long QT syndrome

• Abnormal laboratory results which in the judgment of the investigator would affect the patient's health or the outcome of the trial

• - Has a clinically significant medical condition (other than prostate cancer) including but not limited to: renal, hematological, gastrointestinal, endocrine, cardiac, neurological or psychiatric disease, alcohol or drug abuse or any other condition that may affect the patient's health or the outcome of the trial as judged by the investigator

• Taking Class IA or Class III antiarrhythmic medication

• Has an intellectual incapacity or language barrier precluding adequate understanding or co-operation

• Has received investigational drug within the last 28 days before the Screening visit or longer if considered to possibly influence the outcome of this trial

• Has previously participated in any Ozarelix trials

• Is part of an ongoing trial.

Related Conditions & MeSH terms

• Prostate Cancer
• Prostatic Neoplasms

Intervention

Drug:
• Ozarelix
Ozarelix Loading dose of 130 mg SC at randomization will be followed by maintenance dosing of 65 mg SC at day 8, 28 and 56.
• Goserelin
Goserelin depot 3.6 mg at randomization will be followed by 3.6 mg SC on days 28 and 56.

Locations

Country	Name	City	State
United States	Urology Clinics of North Texas	Dallas	Texas
United States	The Urology Center of Colorado	Denver	Colorado
United States	Urology San Antonio Research	San Antonio	Texas

Sponsors (1)

Lead Sponsor	Collaborator
Spectrum Pharmaceuticals, Inc

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	To assess the percentage of patients with testosterone <=0.5ng/mL.		From Day 28 through Day 84, in men receiving Ozarelix versus Goserelin
Secondary	Percentage change in Prostate-Specific Antigen level	Additional secondary outcomes: Percentage of patients with testosterone level <=0.5 ng/mL at day 3; Median time to reach 50% suppression of baseline Prostate Specific Antigen level; Percentage of patients with testosterone surge ("hormone escape") during the first two weeks of treatment; To assess the safety of Ozarelix SC monthly dosing compared to Goserelin depot SC monthly dosing in men with Prostate Cancer	From baseline to day 14 and day 28